Nasus Pharma Ltd. (NSRX) Stock Score, Valuation & Financial Research

Nasus Pharma Ltd. is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NSRX

Nasus Pharma Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 3.70. These figures are a research snapshot, not a buy or sell recommendation.

What Nasus Pharma Ltd. does

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Nasus Pharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary intranasal powder drug delivery technologies to address acute medical conditions, with the goal of eventually commercializing these products through regulatory approvals and potential partnerships.

Products and services

  • The company develops a portfolio of intranasal powder product candidates, including NS002 (intranasal epinephrine for anaphylaxis), NS001 (intranasal naloxone), NS005 (intranasal midazolam for seizures), NS004 (intranasal atropine for organophosphate poisoning), and NS003 (intranasal ondansetron for vomiting).

Brands and product families

  • Nasax — Proprietary intranasal drug delivery technology platform. Source

Customer types

Healthcare providers and patients requiring acute medical intervention.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and potential future commercial supply. Source

Business strengths to evaluate

  • Proprietary Nasax intranasal powder technology platform Source
  • Focus on needle-free, easy-to-use delivery for acute conditions Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Risks associated with clinical trial success and regulatory approval processes Source
  • Reliance on third-party manufacturers and suppliers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NSRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.70
Market capitalization:
31.87M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.93M
Free cash flow:
USD -4.93M
Cash:
USD 7.82M
Total debt:
USD 103K
EPS:
USD -1.04

What stands out

  • Free cash flow is USD -4.93M, negative for the stored period.
  • The balance sheet shows USD 7.82M of cash versus USD 103K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.72M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NSRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NSRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NSRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NSRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NSRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research NSRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.